Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

恩帕吉菲 达帕格列嗪 医学 卡格列净 危险系数 内科学 置信区间 心力衰竭 糖尿病 倾向得分匹配 2型糖尿病 相对风险 内分泌学
作者
Mikhail Kosiborod,Carolyn S.P. Lam,Shun Kohsaka,Dae Jung Kim,Avraham Karasik,Jonathan E. Shaw,Navdeep Tangri,Su-Yen Goh,Marcus Thuresson,Hungta Chen,Filip Surmont,Niklas Hammar,Peter Fenici
出处
期刊:Journal of the American College of Cardiology [Elsevier]
卷期号:71 (23): 2628-2639 被引量:351
标识
DOI:10.1016/j.jacc.2018.03.009
摘要

Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe.The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Pacific, the Middle East, and North American regions.New users of SGLT-2i and oGLDs were identified via claims, medical records, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, MI, and stroke were assessed by country and pooled using weighted meta-analysis.After propensity-matching, there were 235,064 episodes of treatment initiation in each group; ∼27% had established CV disease. Patient characteristics were well-balanced between groups. Dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin, and luseogliflozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of exposure time in the SGLT-2i group, respectively. Use of SGLT-2i versus oGLDs was associated with a lower risk of death (HR: 0.51; 95% confidence interval [CI]: 0.37 to 0.70; p < 0.001), HHF (HR: 0.64; 95% CI: 0.50 to 0.82; p = 0.001), death or HHF (HR: 0.60; 95% CI: 0.47 to 0.76; p < 0.001), MI (HR: 0.81; 95% CI: 0.74 to 0.88; p < 0.001), and stroke (HR: 0.68; 95% CI: 0.55 to 0.84; p < 0.001). Results were directionally consistent across both countries and patient subgroups, including those with and without CV disease.In this large, international study of patients with T2D from the Asia Pacific, the Middle East, and North America, initiation of SGLT-2i was associated with a lower risk of CV events across a broad range of outcomes and patient characteristics. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
赘婿应助优雅的怀莲采纳,获得10
1秒前
wsx发布了新的文献求助10
2秒前
Jemezs发布了新的文献求助10
3秒前
4秒前
Koi完成签到,获得积分10
5秒前
曾经紫伊完成签到,获得积分10
7秒前
wuzhizhiya完成签到,获得积分10
8秒前
小蘑菇应助11采纳,获得10
8秒前
Singularity发布了新的文献求助10
9秒前
包容的初南完成签到,获得积分10
9秒前
9秒前
大个应助眼睛大迎波采纳,获得10
9秒前
10秒前
10秒前
JamesPei应助Jemezs采纳,获得10
11秒前
水杯不离手完成签到 ,获得积分10
11秒前
帅气的马里奥完成签到 ,获得积分10
11秒前
Biao发布了新的文献求助10
14秒前
科研通AI2S应助11采纳,获得10
15秒前
15秒前
淡然以柳完成签到,获得积分10
19秒前
orange发布了新的文献求助10
20秒前
20秒前
JamesPei应助Biao采纳,获得10
21秒前
22秒前
22秒前
Orange应助Singularity采纳,获得10
24秒前
lhl完成签到,获得积分10
25秒前
26秒前
zzz发布了新的文献求助10
26秒前
zyun完成签到,获得积分10
27秒前
zxldylan完成签到,获得积分10
27秒前
LIUYI发布了新的文献求助10
27秒前
TAN完成签到,获得积分10
29秒前
30秒前
30秒前
33秒前
zzpj发布了新的文献求助10
33秒前
我爱学习发布了新的文献求助10
34秒前
袁青寒发布了新的文献求助10
34秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139146
求助须知:如何正确求助?哪些是违规求助? 2790083
关于积分的说明 7793577
捐赠科研通 2446452
什么是DOI,文献DOI怎么找? 1301175
科研通“疑难数据库(出版商)”最低求助积分说明 626106
版权声明 601102